Sign In
Buy GOVX
$1.32
-0.0200 (-1.49%)
At Close: Jun 22, 2026
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
04:00pm, Tuesday, 06'th Aug 2024
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
10:15am, Wednesday, 31'st Jul 2024
Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor
GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst
12:54pm, Tuesday, 16'th Jul 2024
Geovax Labs (NASDAQ: GOVX ) stock is jumping on Tuesday as investors in GOVX prepare for a catalyst on July 18. That's when Geovax Labs will hold a presentation at the Emerging Growth Conference.
Why Is GeoVax (GOVX) Stock Up 110% Today?
02:23pm, Thursday, 27'th Jun 2024
Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinic
GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript
08:01pm, Tuesday, 14'th May 2024
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Office
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
12:30pm, Thursday, 04'th Apr 2024
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developin
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
09:00am, Thursday, 28'th Mar 2024
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious di
GeoVax to Present at the 36th Annual Roth Conference
09:00am, Tuesday, 12'th Mar 2024
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious di
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
09:00am, Wednesday, 06'th Mar 2024
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
02:34am, Friday, 01'st Mar 2024
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
04:00pm, Thursday, 29'th Feb 2024
Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
09:00am, Thursday, 22'nd Feb 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing im
GeoVax to Present at the 2024 BIO CEO & Investor Conference
09:00am, Monday, 19'th Feb 2024
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dis
GeoVax Announces Multiple Patent Issuances and Allowances
09:00am, Tuesday, 13'th Feb 2024
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
09:00am, Tuesday, 06'th Feb 2024
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechn
